# Repeat expansions in Parkinson's disease and parkinsonism across ancestries: insights from a global genetic cohort.

- **DOI:** [10.64898/2026.06.12.26354932](https://doi.org/10.64898/2026.06.12.26354932)
- **Rating:** Sound (3.7 out of 5)
- **Verdict:** A valuable multi-ancestry map of repeat expansions in parkinsonism, constrained by unresolved reporting inconsistencies around its headline ATXN2 association.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.64898%2F2026.06.12.26354932

## Key claims

1. intermediate ATXN2 repeat expansions exhibited a strong, length-dependent association with PD risk in the European population, with individuals with ≥32 repeats having a more than four-fold increased risk
   - Support: Supported
   - Type: Primary finding
   - Basis: directionally consistent sparse-event association, limited by five controls, threshold scanning, and an unexplained analytic denominator
   - Location: Abstract; Results, Repeat-Length Disease Association Analyses
2. Pathogenic repeat expansions were detected in 62 patients and 5 controls across seven loci, spanning seven ancestries.
   - Support: Supported
   - Type: Secondary
   - Basis: WGS counts are directly enumerated, although additional CES carriers make the combined-cohort framing incomplete
   - Location: Abstract; Results, Pathogenic Repeat Expansions in PD and Atypical Parkinsonism
3. ATXN2 expansions were the most frequently observed in PD and were present in African, East Asian, European and Middle Eastern ancestries.
   - Support: Well-supported
   - Type: Secondary
   - Basis: locus and ancestry counts directly support the ranking and four-ancestry occurrence
   - Location: Abstract; Results, Pathogenic Repeat Expansions in PD and Atypical Parkinsonism
4. Overall, >92% of expanded alleles harbor CAA interruptions within the CAG tract.
   - Support: Tentative
   - Type: Secondary
   - Basis: 92.7% applies to European carriers, while reported frequencies are lower in several other ancestries
   - Location: Abstract; Results, Repeat Motif Structure in Expanded Alleles

## Strengths

- **Large multi-ancestry repeat-expansion map** The analysis spans 38,365 individuals, 12 repeat loci, and 11 genetic ancestries, providing a broader descriptive landscape than prior small or population-specific screens.
  - Dimension: contribution
  - Location: Abstract; Methods, Study Design and Participants; Results, Pathogenic Repeat Expansions
- **Layered molecular validation workflow** Intermediate and pathogenic calls were visually reviewed, selected WGS calls underwent PCR or Sanger validation, ATXN3 calls received Nanopore confirmation, and WGS–CES concordance was assessed in 952 overlapping samples.
  - Dimension: methodological rigour
  - Location: Methods, Repeat Expansion Genotyping
- **Sparse-event analysis and multiplicity control** The threshold analysis used Firth penalized logistic regression and a study-wide Bonferroni threshold across 44 bins, while explicitly identifying instability at the highest ATXN2 cutoff.
  - Dimension: methodological rigour
  - Location: Methods, Repeat-Length Association with PD; Results, Repeat-Length Disease Association Analyses

## Limitations

- **Headline analysis denominators do not reconcile** The Abstract reports 15,995 European participants in the threshold analysis, whereas the Results report 14,720, leaving the final analytic denominator for the headline association unexplained.
  - Dimension: reporting
  - Location: Abstract; Results, Repeat-Length Disease Association Analyses
- **Central abstract claims exceed analyses** The reported “>92% overall” interruption rate corresponds only to European carriers, and structure-dependent risk is asserted without comparing interruption patterns between cases and controls.
  - Dimension: reporting
  - Location: Abstract; Results, Repeat Motif Structure in Expanded Alleles
- **Association rests on sparse heterogeneous cohorts** The ≥32 ATXN2 estimate is based on 26 patients and five controls, while cases and controls include different source datasets and sequencing protocols that are not directly examined in the association model.
  - Dimension: methodological rigour
  - Location: Methods, Study Design and Participants and Repeat-Length Association with PD; Results, Repeat-Length Disease Association Analyses

## Reliability checks

Concerns (4 of 4 checks).

- **Results check:** Concern
  - intermediate ATXN2 repeat expansions exhibited a strong, length-dependent association with PD risk in the European population, with individuals with ≥32 repeats having a more than four-fold increased risk: "Additionally, we conducted threshold-based associations to determine the minimum threshold associated with increased PD risk in 15,995 individuals (8,591 PD, 7,404 controls) of European ancestry." (Abstract) vs "Using Firth’s penalized logistic regression adjusted for sex and the first five principal components in 7,963 European PD patients and 6,757 controls, we observed a significant association between expanded ATXN2 repeat length and PD risk across multiple length thresholds after Bonferroni correction for multiple testing (Figure 4; Supplementary Table 4). At a threshold of ≥32 repeats (26 patients, 5 controls), carriers had a more than four-fold increased risk of PD compared with non-carriers (odds ratio [OR] = 4.25, 95% CI: 1.80 to 12.05, P = 0.00057)." (Results, Repeat-length disease association analyses). The Results give 7,963 + 6,757 = 14,720 analyzed participants, 1,275 fewer than the abstract's 15,995, while explicitly reporting OR = 4.25 and P = 0.00057 for that smaller sample. → Conclusion holds
  - Overall, >92% of expanded alleles harbor CAA interruptions within the CAG tract: "Overall, >92% of expanded alleles harbor CAA interruptions within the CAG tract." (Abstract) vs "Among European carriers of expanded alleles (≥32 repeats) across phenotypes, 92.7% (38/41) contained one or more CAA interruptions within the CAG tract. The frequency of interruptions differed across ancestries, occurring in 76.5% (13/17) of EAS carriers and 66.7% (4/6) of AFR carriers. All expanded allele carriers of AAC (4/4), AMR (1/1), CAS (1/1) and MDE (1/1) ancestry also harbored at least one CAA interruption; however, these estimates should be interpreted cautiously given the limited sample sizes in non-European ancestries. Similarly, 88.5% (23/26) of ATXN2 expanded allele carriers identified from non-overlapping PD patients with CES data contained at least one CAA interruption." (Results, Repeat motif structure in expanded alleles). Pooling the reported ancestry counts gives (38 + 13 + 4 + 4 + 1 + 1 + 1)/(41 + 17 + 6 + 4 + 1 + 1 + 1) = 62/71 = 87.3%, or (62 + 23)/(71 + 26) = 85/97 = 87.6% when non-overlapping CES carriers are included. → Not supported by the paper's own data
  - Pathogenic repeat expansions were detected in 62 patients and 5 controls across seven loci, spanning seven ancestries: "Pathogenic repeat expansions were detected in 62 patients (56 PD and 6 atypical parkinsonism) and 5 controls across seven loci (AR, ATXN1, ATXN2, ATXN3, CACNA1A, HTT and THAP11), spanning seven ancestries." (Abstract) vs "Among the 9,504 non-overlapping PD patients with CES data (no genetic ancestry prediction available), pathogenic repeat expansions were identified in ATXN2 (n=6, 0.06%), CACNA1A (n=1, 0.01%) and AR (n=6, 0.06%)." (Results, Pathogenic repeat expansions in PD and atypical parkinsonism). The non-overlapping CES cohort adds 6 + 1 + 6 = 13 PD carriers to the abstract's 62 patients, giving 75 patients and 5 controls across the combined cohort. → Changes the size materially
  - Minor reporting notes (1):
    - Descriptive: "Additionally, we included 10,454 CES samples with clinical exome alignment data as part of GP2 Data Release 8." (Methods, Whole-genome and clinical exome sequencing datasets) vs "After removing CES samples identified as genetic duplicates of WGS individuals, a final set of 9,504 CES samples was retained for screening, with the 952 genetic duplicates used to assess the accuracy of CES repeat genotyping." (Methods, Whole-genome and clinical exome sequencing datasets). Subtracting the stated 952 duplicates from 10,454 CES samples yields 9,502 rather than 9,504, a difference of two samples. → Conclusion holds
- **Reporting and transparency:** Clean. No reporting or research-conduct concerns were raised for retention.
  - Conflict of interest: not stated · Ethics approval: declared · Preregistration: not stated · Data availability: declared · Code availability: declared
- **Reference integrity:** Clean
  - 57 references in manuscript
  - 57 of 57 checkable references found in an index
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
